• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Association of complementary medicine, cancer treatment, survival

Bioengineer by Bioengineer
July 19, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bottom Line: The use of complementary medicine by patients with four common cancers (breast, prostate, lung or colorectal) was associated with refusal of conventional cancer treatment and with a greater risk of death, although the difference in survival may be alleviated by adherence to all recommended conventional cancer therapies.

Why The Research Is Interesting: Complementary medicine is intended to be used in addition to conventional cancer therapy. Patients use a wide variety of complementary medicine, which can include herbs and botanicals, vitamins and minerals, traditional Chinese medicine, specialized diets, homeopathy and naturopathy, to improve their quality of life and with the hope of prolonging it. This study used a large national database to examine the use of complementary medicine by patients and delays in, or refusal of, conventional cancer therapies

Who and When: From among 1.9 million patients in the National Cancer Database, 258 patients who used complementary medicine were compared with 1,032 who didn't; patients were diagnosed with nonmetastatic breast, prostate, lung or colorectal cancer between 2004 and 2013

What (Study Measures and Outcomes): Use of complementary medicine (defined as "other-unproven: cancer treatments administered by nonmedical personnel") in addition to at least one conventional cancer therapy, which was defined as surgery, radiotherapy, chemotherapy or hormone therapy (exposures); overall survival, adherence to treatment and patient characteristics (outcomes)

Study Design: This was an observational study. Researchers were not intervening for purposes of the study and cannot totally control for all the natural differences that could explain the study results.

Authors: Skyler B. Johnson M.D., and James B. Yu, M.D., M.H.S., and coauthors at the Yale School of Medicine, New Haven, Connecticut

Limitations: The use of complementary medicine by patients was likely understated because patients are often hesitant to report its use to their clinicians; other factors unaccounted for could have influenced survival; and there are inherent limitations in the study's design

###

To Learn More: The full study is available on the For The Media website.

(doi:10.1001/jamaoncol.2018.2487)

Editor's Note: The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Want to embed a link to this study in your story?: Links will be live at the embargo time http://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2018.2487

Media Contact

Anne Doerr
[email protected]

@JAMAOnc

Share13Tweet8Share2ShareShareShare2

Related Posts

Stilbenes in Cancer Therapy: Molecular Targets, Progress

September 23, 2025
blank

New PET Tracer Allows Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers

September 22, 2025

Dr. Scott Eggener Appointed Chair of Urology at UCLA Health, Advancing Urologic Oncology Leadership

September 22, 2025

Severe Obesity Linked to Lower Rates of Recommended Cancer Screenings

September 22, 2025
Please login to join discussion

POPULAR NEWS

  • Physicists Develop Visible Time Crystal for the First Time

    Physicists Develop Visible Time Crystal for the First Time

    69 shares
    Share 28 Tweet 17
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    50 shares
    Share 20 Tweet 13
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Stilbenes in Cancer Therapy: Molecular Targets, Progress

Volumetric Capacitance Transforms Organic Electrochemical Transistor Models

Metformin Combinations Show Promise in Lung Cancer

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.